Structure Therapeutics posts positive early data for oral weight-loss program
Structure Therapeutics reported Phase 1/2a SAD results for ACCG-2671, an oral amylin receptor agonist, citing ~6-day half-life, no serious adverse events, and target engagement including up to 3.3% body weight loss.
Story updates
12:13:53 PM UTC
SquawkNews
Structure Therapeutics reported positive topline SAD results for ACCG-2671 and durable 72-week weight-loss results for aleniglipron.Key Highlights:Original SEC Filing: Structure Therapeutics Inc. [ GPCR ] - 8-K - Sep. 08, 2026This is an AI-powered summary. It may contain inaccuracies. Consider veri…
ACCG-2671, an oral small molecule amylin receptor agonist, showed a ~6-day half-life and no serious adverse events in a Phase 1/2a SAD clinical trial. 3% body weight loss. The first participants were dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a study.